Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion

Background Interleukin-6 (IL-6) levels are upregulated in myocardial infarction. Recent data suggest a causal role of the IL-6 receptor (IL-6R) in coronary heart disease. We evaluated if IL-6R blockade by a monoclonal antibody (MR16-1) prevents the heart from adverse left ventricular remodeling in a mouse model of ischemia-reperfusion (I/R). Methods CJ57/BL6 mice underwent I/R injury (left coronary artery ligation for 45 minutes) or sham surgery, and thereafter received MR16-1 (2mg/mouse) 5 minutes before reperfusion and 0.5mg/mouse weekly during four weeks, or control IgG treatment. Cardiac Magnetic Resonance Imaging (CMR) and hemodynamic measurements were performed to determine cardiac function after four weeks. Results I/R caused left ventricular dilatation and a decrease in left ventricular ejection fraction (LVEF). However, LVEF was significantly lower in the MR16-1 treatment group compared to the IgG group (28 +/- 4% vs. 35 +/- 6%, p = 0.02; sham 45 +/- 6% vs. 43 +/- 4%, respectively; p = NS). Cardiac relaxation (assessed by dP/dT) was not significantly different between the MR16-1 and IgG groups. Also, no differences were observed in histological myocardial fibrosis, infarct size and myocyte hypertrophy between the groups. Conclusion Blockade of the IL-6R receptor by the monoclonal MR16-1 antibody for four weeks started directly after I/R injury did not prevent the process of cardiac remodeling in mice, but rather associated with a deterioration in the process of adverse cardiac remodeling

Young AF

Phenotyping young-onset atrial fibrillation patients (Young-AF) study and bioban

VIP-HF

Ventricular tachyarrhythmia detection by Pmplantable loop recording in Patients with Heart Failure and preserved ejection fraction (VIP-HF) registr

VIP-HF

Ventricular tachyarrhythmia detection by Pmplantable loop recording in Patients with Heart Failure and preserved ejection fraction (VIP-HF) registr

Biomarker AF

Identification of a risk profile to guide atrial fibrillation therapy in patients with AF (Biomarker AF) registry and bioban

Biomarker AF

Identification of a risk profile to guide atrial fibrillation therapy in patients with AF (Biomarker AF) registry and bioban

Hybrid AF

Identification of a Risk Profile Associated with Failure of the Hybrid Ablation of Atrial Fibrillation registry and bioban

MARC

Markers and Response to CRT (MARC) stud

RACE V

Reappraisal of AF: Interaction Between HyperCoagulability, Electrical Remodelling, and Vascular Destabilisation in the Progression of AF (RACE V) registr

Hybrid AF

Identification of a Risk Profile Associated with Failure of the Hybrid Ablation of Atrial Fibrillation registry and bioban